Total planned funding: $285,425,714
Clear active filters
U.S. Centers for Disease Control and Prevention
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
Allocations
Countries/Regions
| Uganda | $29,831,003 |
| Kenya | $24,010,472 |
| Ethiopia | $23,808,600 |
| Nigeria | $21,487,520 |
| Côte d'Ivoire | $21,044,086 |
| Mozambique | $20,365,608 |
| Tanzania | $19,050,425 |
| Zambia | $18,447,001 |
| Botswana | $17,988,711 |
| South Africa | $16,639,674 |
| Rwanda | $10,532,801 |
| Vietnam | $9,839,374 |
| Haiti | $9,573,000 |
| Namibia | $7,110,425 |
| Caribbean Region | $6,472,463 |
| Zimbabwe | $4,265,000 |
| Guyana | $4,041,620 |
| Thailand | $3,170,179 |
| Malawi | $2,751,475 |
| India | $2,224,116 |
| Angola | $2,040,000 |
| Cambodia | $2,009,870 |
| Dominican Republic | $2,004,565 |
| South Sudan | $1,503,000 |
| Eswatini | $1,430,409 |
| Democratic Republic of the Congo | $1,378,317 |
| Lesotho | $835,000 |
| Ghana | $631,000 |
| Russia | $500,000 |
| China | $440,000 |
Organizational Types
| Own Agency | $285,425,714 |
Program Areas
| Management and Operations | $145,586,678 |
| Governance and Systems | $77,864,529 |
| Prevention | $22,352,570 |
| Care | $16,956,706 |
| Treatment | $16,938,986 |
| Testing | $5,726,245 |
Budget Codes
| HVMS: Management and Operations | $145,586,678 |
| HVSI: Strategic Information | $42,554,242 |
| HLAB: Laboratory Infrastructure | $25,355,031 |
| HTXS: Treatment: Adult Treatment | $16,272,289 |
| HVTB: Care: TB/HIV | $10,352,888 |
| OHSS: Health Systems Strengthening | $9,955,256 |
| MTCT: Biomedical Prevention: Prevention of Mother to Child Transmission | $9,478,791 |
| HVAB: Sexual Prevention: Abstinence/Be Faithful | $5,940,851 |
| HVCT: Testing: HIV Testing and Counseling | $5,726,245 |
| HBHC: Care: Adult Care and Support | $5,523,118 |
| HVOP: Sexual Prevention: Other Sexual Prevention | $4,371,136 |
| HMBL: Biomedical Prevention: Blood Safety | $1,769,792 |
| HKID: Care: Orphans and Vulnerable Children | $1,080,700 |
| HMIN: Biomedical Prevention: Injection Safety | $792,000 |
| HTXD: Treatment: ARV Drugs | $666,697 |